Compare CHRW & WST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CHRW | WST |
|---|---|---|
| Founded | 1905 | 1923 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil Refining/Marketing | Medical/Dental Instruments |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 23.0B | 18.5B |
| IPO Year | 1997 | 2004 |
| Metric | CHRW | WST |
|---|---|---|
| Price | $171.21 | $323.91 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 20 | 7 |
| Target Price | $181.05 | ★ $325.86 |
| AVG Volume (30 Days) | ★ 2.0M | 919.8K |
| Earning Date | 04-29-2026 | 04-23-2026 |
| Dividend Yield | ★ 1.35% | 0.30% |
| EPS Growth | ★ 25.13 | 1.49 |
| EPS | 1.22 | ★ 1.92 |
| Revenue | ★ $14,869,380,000.00 | $2,886,900,000.00 |
| Revenue This Year | $5.07 | $6.76 |
| Revenue Next Year | $6.26 | $6.22 |
| P/E Ratio | ★ $140.22 | $170.25 |
| Revenue Growth | N/A | ★ 1.95 |
| 52 Week Low | $92.36 | $203.74 |
| 52 Week High | $203.34 | $328.44 |
| Indicator | CHRW | WST |
|---|---|---|
| Relative Strength Index (RSI) | 45.66 | 74.63 |
| Support Level | $159.88 | $234.43 |
| Resistance Level | $175.74 | N/A |
| Average True Range (ATR) | 5.54 | 9.31 |
| MACD | -1.39 | 2.20 |
| Stochastic Oscillator | 38.47 | 87.39 |
C.H. Robinson is a top-tier non-asset-based third-party logistics provider with a significant focus on domestic freight brokerage (about 60% of net revenue), which reflects mostly truck brokerage but also rail intermodal. Additionally, the firm operates a large air and ocean forwarding division (30%), which has grown organically and via tuck-in acquisitions over the years. The remainder of revenue consists of transportation management services and a legacy produce-sourcing operation.
West Pharmaceutical Services is based in Pennsylvania and is a key supplier to firms in the pharmaceutical, biotechnology, and generic drug industries. West sells elastomer-based packaging components (including stoppers, seals, and plungers), nonglass containment solutions, and auto-injectors for injectable drugs, which include large-molecule biologics, peptides such as GLP-1 receptor agonists, and small-molecule drugs. The company reports in two segments: proprietary products (about 80% of total revenue) and contract-manufactured products (about 20% of total revenue). It generates approximately 55% of its revenue from international markets and 45% from the United States.